TransCode Therapeutics, Inc.

0.22 USD
+0.01 (+7.01%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

TransCode Therapeutics, Inc. stock is down -43.39% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 December’s closed higher than November.

About TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. engages in the development and commercialization of drugs and diagnostics. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company was incorporated in 2016 and is based in Boston, Massachusetts.